Lopez-Campos, Jose LuisMarquez-Martin, EduardoCasanova, Ciro2023-01-252023-01-252016-08-31Lopez-Campos JL, Márquez-Martín E, Casanova C. Beta-blockers and COPD: the show must go on. Eur Respir J. 2016 Sep;48(3):600-3.http://hdl.handle.net/10668/10406Identification of comorbidities is now recognised as one of the pillars for a comprehensive clinical evaluation in chronic obstructive pulmonary disease (COPD) [1]. Specifically, the burden of coexisting cardiovascular disease in COPD has gained significant attention, with specific algorithms being developed for its clinical detection [2]. The relationship between the heart and COPD is of clinical relevance not only for the well-documented relationship between the two organs [3], but also for the potential mutual influence of treatments. The interactions between oral beta-blockers and inhaled β-adrenergic drugs pose significant challenges for clinicians involved in the management of patients with chronic cardiorespiratory conditions. In particular, the use of beta-blockers in COPD remains the subject of ongoing controversyenAdrenergic AgentsClinical RelevanceCardiovascular DiseasesHeartAdrenergic beta-AntagonistsHumansPulmonary Disease, Chronic Obstructiveeditorial27581400Restricted AccessEnfermedad Pulmonar Obstructiva CrónicaPacientesCorazónDiagnósticoEnfermedades cardiovascularesRelevancia clínicaAdrenérgicosAtención10.1183/13993003.01222-20161399-3003https://erj.ersjournals.com/content/erj/48/3/600.full.pdf